The patent protects ActaSim’s design that allows surgeons to use it with ease.
“Receiving the patent is important. It’s also validating seeing the AcatStim-S design so well received by patients and surgeons,” Chris McAuliffe, Theragen’s CEO, said in an Oct. 4 press release. “Our first patent focused on device connectivity, while this patent protects our device design. ActaStim-S offers significant practical advantages versus large, obtrusive devices that can constrain ambulation and mobility.”
